Cogstate Limited, a cognitive science company, provides computerized cognitive tests for clinical trials, academic research, healthcare, and brain health applications in Australia and internationally.
Excellent balance sheet and overvalued.
Share Price & News
How has Cogstate's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CGS's share price has been volatile over the past 3 months.
7 Day Return
AU Healthcare Services
1 Year Return
AU Healthcare Services
Return vs Industry: CGS exceeded the Australian Healthcare Services industry which returned 19% over the past year.
Return vs Market: CGS exceeded the Australian Market which returned -10.6% over the past year.
Price Volatility Vs. Market
How volatile is Cogstate's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall StDo Institutions Own Cogstate Limited (ASX:CGS) Shares?
4 weeks ago | Simply Wall StIs Cogstate Limited's (ASX:CGS) CEO Pay Fair?
1 month ago | Simply Wall StDid Cogstate's (ASX:CGS) Share Price Deserve to Gain 100%?
Is Cogstate undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CGS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CGS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CGS is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.
PE vs Market: CGS is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CGS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CGS is good value based on its PB Ratio (2.3x) compared to the AU Healthcare Services industry average (4x).
How is Cogstate forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cogstate has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Cogstate's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Cogstate competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has Cogstate performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CGS is currently unprofitable.
Growing Profit Margin: CGS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CGS is unprofitable, and losses have increased over the past 5 years at a rate of -6.6% per year.
Accelerating Growth: Unable to compare CGS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CGS is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (10%).
Return on Equity
High ROE: CGS has a negative Return on Equity (-16.94%), as it is currently unprofitable.
How is Cogstate's financial position?
Financial Position Analysis
Short Term Liabilities: CGS's short term assets ($14.8M) exceed its short term liabilities ($11.9M).
Long Term Liabilities: CGS's short term assets ($14.8M) exceed its long term liabilities ($2.9M).
Debt to Equity History and Analysis
Debt Level: CGS's debt to equity ratio (5.6%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if CGS's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CGS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CGS has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 6.7% each year.
What is Cogstate's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CGS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CGS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CGS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CGS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CGS's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Bradley O'Connor, also known as Brad, B.Bus, CA, has been the Chief Executive Officer and Managing Director of Cogstate Limited since December 1, 2005 and served as its Chief Financial Officer since Ma ...
CEO Compensation Analysis
Compensation vs Market: Brad's total compensation ($USD655.04K) is above average for companies of similar size in the Australian market ($USD252.51K).
Compensation vs Earnings: Brad's compensation has been consistent with company performance over the past year.
|CEO, MD & Executive Director||14.42yrs||US$655.04k||3.45% $1.8m|
|Chief Technology Officer||3.17yrs||US$391.34k||no data|
|Chief Scientific Officer||no data||US$416.58k||0.29% $155.0k|
|Senior Vice President of Clinical Science||2.17yrs||no data||no data|
|Chief Commercial Officer||0.42yr||no data||no data|
|Company Secretary||0.42yr||no data||no data|
|Principal Consultant||no data||no data||no data|
Experienced Management: CGS's management team is considered experienced (2.2 years average tenure).
|CEO, MD & Executive Director||14.42yrs||US$655.04k||3.45% $1.8m|
|Independent Non-Executive Director||9.75yrs||US$64.79k||2.53% $1.3m|
|Non-Executive Chairman||no data||US$101.51k||13.88% $7.3m|
|Independent Non-Executive Director||0.75yr||no data||0.079% $41.6k|
|Independent Non-Executive Director||6.42yrs||US$65.15k||15.12% $8.0m|
|Independent Non-Executive Director||3.33yrs||US$52.98k||0.032% $17.1k|
Experienced Board: CGS's board of directors are considered experienced (6.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 42.7%.
Cogstate Limited's company bio, employee growth, exchange listings and data sources
- Name: Cogstate Limited
- Ticker: CGS
- Exchange: ASX
- Founded: 1999
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: AU$52.745m
- Shares outstanding: 170.15m
- Website: https://www.cogstate.com
Number of Employees
- Cogstate Limited
- 255 Bourke Street
- Level 2
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CGS||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Feb 2004|
|COGZ.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Feb 2004|
|CGS||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Feb 2004|
Cogstate Limited, a cognitive science company, provides computerized cognitive tests for clinical trials, academic research, healthcare, and brain health applications in Australia and internationally. The company’s services include scientific consultancy, project management, data management, statistical analysis, and reporting. It operates in three segments: Clinical Trials, Academic Research, and Healthcare. The Clinical Trials segment provides technology and associated services that are used to quantify the effect of diseases and drugs, and devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The Academic Research segment offers technology and associated services to support international research studies and academic collaborations across various indications, including Alzheimer’s disease, HIV, multiple sclerosis, pediatric and adult oncology, Parkinson’s disease, epilepsy, and schizophrenia. As of June 30, 2019, it had participated in approximately 1,400 academic research studies in approximately 150 indications. The Healthcare segment provides Cognigram, a system for regular and standardized testing to assist in the early detection of cognitive decline. The company serves biopharmaceutical companies, sporting organizations, military, physicians and patients, academic institutions, and public-private partnerships. Cogstate Limited has a license agreement with Eisai Co., Ltd. Cogstate Limited was founded in 1999 and is headquartered in Melbourne, Australia.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/31 10:36|
|End of Day Share Price||2020/05/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.